Quality Investor

RLX Technology Inc.

Rank #436HypergrowthWatchlistCompare with other stocks

RLX · NYSE · Consumer Defensive

RLX Technology Inc. (RLX) — Rank #436 by gross profitability (GP/assets 0.07) · ROE 5.9% · Piotroski F-Score 7 / 9.

As-of 2026-10-30 · CIK 0001828365 · all metrics point-in-time as of the filing date.

About

RLX Technology Inc., through its subsidiaries, develops, manufactures, and sells e-vapor products in the People's Republic of China and internationally.

Show more

It offers rechargeable e-vapor products under the Qingyu, Phantom, Phantom Pro, Zeus, Leili, and Daqian names; and disposable e-vapor products under the Feiliu and Feiliu Mega names. The company also provides closed-system rechargeable products, open-system products, closed-system disposable products, and modern oral products. It sells its products through local channels, third-party distribution channels, and distribution channels co-managed with third parties, as well as online and offline end users.

The company was founded in 2018 and is headquartered in Shenzhen, the People's Republic of China.

Industry
Tobacco
Sector
Consumer Defensive
State
E9
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/S is the primary valuation lens — earnings are reinvested, not available for P/E.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

897

Industry

Tobacco

Exchange

NYSE

12/12

Flags passed

RLX passes 12/12 quality flags

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Deferred revenue growing

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.07
Return on equity
5.9%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.14
Current ratio
5.70×
Net cash
$7.61B

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
4.7%

Growth

2/2 pass
Revenue growth
44.0%
Piotroski F-Score
7 / 9
Share dilution
-5.0%

Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 0.07

Gross profitability (GP / assets)

0.07

Primary signal (Novy-Marx).

Return on equity

5.9%

Gross margin

29.9%

Revenue growth (YoY)

44.0%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

-9.5%

Revenue CAGR (5Y)

0.7%

Earnings CAGR (3Y)

-13.8%

FCF CAGR (3Y)

30.1%

Cash Flow Health

Is the cash real?

No warning flags · FCF 7% above net income

Free cash flow

$986.82M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

7.0%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

4.7%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net cash $7.61B, F-Score 7/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.14

Current ratio

5.70×

Quick ratio

—

Net cash

$7.61B

Cash & equivalents minus total debt.

Piotroski F-Score

7 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Dividend safety

Composite score

4.0 / 5

Strong
Payout ratio
9.9%5/5 Strong
FCF coverage
10.79×5/5 Strong
Dividend growth streak
1 yr1/5 Weak
Balance-sheet health
D/E 0.14 · IC 51.38×5/5 Strong

Capital allocation quality

Composite score

3.7 / 5

Good
Share count trend(net buybacks)
-5.0%5/5 Strong
Buyback timing
N/AN/A
Dividend growth consistency
1 yr1/5 Weak
Net debt trajectory(deleveraging)
7.4%5/5 Strong

Lifecycle Phase History

20202025
Hypergrowth
Decline

Price History

RLX-66.8% · -19.7% CAGRSPY+82.9% · +12.8% CAGR